Journal ArticleDOI
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
TLDR
There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B.About:
This article is published in Journal of Hepatology.The article was published on 2008-02-01. It has received 1172 citations till now. The article focuses on the topics: HBeAg & Hepatitis B.read more
Citations
More filters
Journal ArticleDOI
A cost-consequence analysis of hepatitis B screening in an immigrant population.
Alessandra Buja,Diego Martines,S. Lobello,Angela Vinelli,G. Bardelle,Stefania Lopatriello,Franca De Lazzari,Lionel Perrier,Vincenzo Baldo +8 more
TL;DR: In this paper, a cost-consequence analysis of an HBV screening strategy was conducted in a cohort of adult migrants in the province of Padua, northern Italy, where the population targeted for screening consisted of 65405 migrants, among whom the weighted rate for the prevalence of HBV was 0.04972.
Posted Content
A cost-consequence analysis of hepatitis B screening in an immigrant population
TL;DR: Screening for HBV among groups at risk, such as migrant populations, has proved to be a cost-effective strategy and provides useful information to policy-makers at local and regional levels.
Journal ArticleDOI
Correlation between viral load and liver cirrhosis in chronic hepatitis B patients
Li-li Liu,Jiyao Wang,Wei-min She +2 more
TL;DR: The results of Cox model indicated that HBV-DNA levels at endpoint, stage of fibrosis, negative hepatitis B e antigen, and γ-glutamyl transpeptidase at baseline were independent risk factors of cirrhosis.
Journal ArticleDOI
CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy.
Paola Giarda,Anchalee Avihingsanon,Joe Sasadeusz,Jennifer Audsley,P. Marks,Gail V. Matthews,Kiat Ruxrungtham,Sharon R Lewin,Megan Crane +8 more
TL;DR: No evidence was found that CXCL-10, IL-12 or IL-21 were associated with HBeAg seroconversion following HBV-active cART, and other immunological determinants should be explored in this setting.
Journal ArticleDOI
Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial.
Qing-Juan Wu,Wenliang Lv,Juan-Mei Li,Ting-Ting Zhang,Wen-Hui Zhou,Qiang Zhang,Jiu-Chong Wang,Qing-Nan Wang,Ruo-Xuan Zhang,Ruo-Xuan Zhang,Xin Zhao,Xin Zhao,Si-Tong Chen,Si-Tong Chen,Shuang Liu,Gao-Hui Li,Zheng-Min Cao,Zheng-Min Cao,lei xu,lei xu,Jing Chen +20 more
TL;DR: Combination therapy could become a trend for treatment ofCHB, and this trial expects to provide credible clinical evidence for the future combination of TCM and conventional antiviral drugs for the treatment of CHB.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Chronic hepatitis B
Anna S. Lok,Brian J. McMahon +1 more
TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
Journal ArticleDOI
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
TL;DR: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
Journal ArticleDOI
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
TL;DR: Further studies are needed to investigate other viral factors (eg, HBV genotype/mutant, occult HBV, HIV coinfection) and preventable or treatable comorbidities ( eg, obesity, diabetes) in the HCC risk in cirrhosis.